Shire’s multi­bil­lion-dol­lar gam­ble on lanadelum­ab pays off with stel­lar PhI­II da­ta, quick mar­ket­ing ap­pli­ca­tion

When Shire bought out Dyax for up to $6.5 bil­lion in 2015, the big prize was a new drug for hered­i­tary an­gioede­ma dubbed DX-2930 which posed a di­rect threat to Cin­ryze, a fran­chise drug for the rare dis­ease play­er.

Thurs­day morn­ing, Shire CEO Flem­ming Orn­skov says their mul­ti-bil­lion dol­lar bet paid off with stel­lar Phase III da­ta for the drug, now called lanadelum­ab (SHP643).

A 300 mg dose of the drug twice a month de­liv­ered an 87% re­duc­tion in mean HAE at­tack fre­quen­cy, com­pared to 0% in the place­bo group. It hit the pri­ma­ry end­point with “high­ly” sta­tis­ti­cal­ly sig­nif­i­cant re­sults as well as all the sec­on­daries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.